These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17189867)

  • 1. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone.
    Garg R; Gopal J; Jones GR
    J Diabetes Complications; 2007; 21(1):1-6. PubMed ID: 17189867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.
    Hollander P; Yu D; Chou HS
    Arch Intern Med; 2007 Jun; 167(12):1284-90. PubMed ID: 17592102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
    Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
    Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
    Orbay E; Sargin M; Sargin H; Gözü H; Bayramiçli OU; Yayla A
    Endocr J; 2004 Dec; 51(6):521-7. PubMed ID: 15644569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
    Rosenstock J; Niggli M; Maldonado-Lutomirsky M
    Diabetes Obes Metab; 2009 Jun; 11(6):571-8. PubMed ID: 19383032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.
    Reynolds LR; Kingsley FJ; Karounos DG; Tannock LR
    Diabetes Res Clin Pract; 2007 Aug; 77(2):180-7. PubMed ID: 17239474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.
    Naka KK; Papathanassiou K; Bechlioulis A; Pappas K; Kazakos N; Kanioglou C; Papafaklis MI; Kostoula A; Vezyraki P; Makriyiannis D; Tsatsoulis A; Michalis LK
    Diab Vasc Dis Res; 2011 Jul; 8(3):195-201. PubMed ID: 21576196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
    Chogtu B; Singh NP; Chawla S; Gupta U
    Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.